- $3.11bn
- $3.01bn
- $158.32m
Brief: Liquidia says US FDA Grants Tentative Approval Of Yutrepia For Patients With Pulmonary Arterial Hypertension And Pulmonary Hypertension Associated With Interstitial Lung Disease
Liquidia slumps as US FDA holds back final approval for blood pressure drug
US FDA grants tentative approval to Liquidia's inhaled blood pressure drug (updated)
US FDA grants tentative approval to Liquidia's inhaled blood pressure drug
Liquidia Corp reports results for the quarter ended in June - Earnings Summary
Liquidia Corp expected to post a loss of 34 cents a share - Earnings Preview
Brief: Liquidia Corp Files For Resale Of Up To 7.3 Million Shares By The Selling Stockholders - SEC Filing
U.S. RESEARCH ROUNDUP- Altus Power, Jack in the Box, Home Depot
U.S. RESEARCH ROUNDUP- Altus Power, Jack in the Box, Home Depot
Liquidia Corp reports results for the quarter ended in January - Earnings Summary
Liquidia Corp expected to post a loss of 32 cents a share - Earnings Preview
Liquidia Corp expected to post a loss of 32 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Guess, Crypto stocks, Liquidia
Liquidia Corp rises on plans to seek full approval for blood disorder drug
U.S. STOCKS ON THE MOVE-Netflix, Reddit, Stoke Therapeutics
U.S. STOCKS ON THE MOVE-Spirit Airlines, Cintas, Reddit
Liquidia falls as rival Merck's therapy for lung condition gets FDA approval
Liquidia Corp reports results for the quarter ended in December - Earnings Summary
Liquidia Corp expected to post a loss of 24 cents a share - Earnings Preview